Public companies continued to ride the crest of the wave of financing, licensing deals and regulatory approvals, but clouds may be looming on the horizon for the biggest biotech players. Chris Morrison and Riku Lähteenmäki report.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Supplementary information
Supplementary Table 1
2018 data
Rights and permissions
About this article
Cite this article
Morrison, C., Lähteenmäki, R. Public biotech 2018—the numbers. Nat Biotechnol 37, 714–721 (2019). https://doi.org/10.1038/s41587-019-0170-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0170-7
This article is cited by
-
Assessing progress in biotech’s gender balance
Nature Biotechnology (2020)